blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3804711

EP3804711 - METHODS OF TREATING MULTIPLE SCLEROSIS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  28.04.2023
Database last updated on 09.04.2026
FormerExamination is in progress
Status updated on  05.11.2021
FormerRequest for examination was made
Status updated on  16.07.2021
FormerThe application has been published
Status updated on  12.03.2021
Most recent event   Tooltip28.04.2023Application deemed to be withdrawnpublished on 31.05.2023  [2023/22]
Applicant(s)For all designated states
Biogen MA Inc.
225 Binney Street
Cambridge, MA 02142 / US
[2021/15]
Inventor(s)01 / NOVAS, Mark
172 East Emerson Road
Lexington, MA Massachusetts 02420 / US
02 / ZHANG, Rui, (Ray)
26 Horizons Road
Sharon, MA Massachusetts 02067 / US
 [2021/15]
Representative(s)Pohlman, Sandra M.
df-mp Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
[N/P]
Former [2021/15]Pohlman, Sandra M.
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstrasse 16
80333 München / DE
Application number, filing date20195649.716.11.2015
[2021/15]
Priority number, dateUS201462080783P17.11.2014         Original published format: US 201462080783 P
US201562140255P30.03.2015         Original published format: US 201562140255 P
US201562232963P25.09.2015         Original published format: US 201562232963 P
[2021/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3804711
Date:14.04.2021
Language:EN
[2021/15]
Search report(s)(Supplementary) European search report - dispatched on:EP11.03.2021
ClassificationIPC:A61K31/225, A61P25/02
[2021/15]
CPC:
A61K31/225 (EP,CN,IL,KR,US); A61K47/542 (IL,US); A61K47/545 (IL,US);
A61K49/0004 (IL); A61K9/0053 (IL,US); A61K9/20 (IL);
A61K9/28 (IL,US); A61K9/48 (IL); A61K9/4808 (IL,US);
A61K9/4825 (IL,US); A61K9/485 (IL,US); A61K9/4858 (IL,US);
A61K9/4866 (IL,US); A61P21/00 (EP,IL); A61P25/00 (EP,IL,US);
A61P25/02 (EP,IL); A61P25/28 (EP,IL,KR); A61P37/00 (KR);
A61P37/02 (EP,IL); G01N33/492 (EP,IL,US); G09B19/00 (IL,US);
Y02A50/30 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/33]
Former [2021/15]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA12.07.2021
ME12.07.2021
Validation statesMA12.07.2021
MD12.07.2021
TitleGerman:VERFAHREN ZUR BEHANDLUNG VON MULTIPLER SKLEROSE[2021/15]
English:METHODS OF TREATING MULTIPLE SCLEROSIS[2021/15]
French:MÉTHODES DE TRAITEMENT DE LA SCLÉROSE EN PLAQUES[2021/15]
Examination procedure12.07.2021Amendment by applicant (claims and/or description)
12.07.2021Examination requested  [2021/33]
12.07.2021Date on which the examining division has become responsible
04.11.2021Despatch of a communication from the examining division (Time limit: M04)
16.02.2022Reply to a communication from the examining division
06.04.2022Observations by third parties
24.06.2022Despatch of a communication from the examining division (Time limit: M06)
05.01.2023Application deemed to be withdrawn, date of legal effect  [2023/22]
26.01.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2023/22]
Parent application(s)   TooltipEP15804260.6  / EP3220907
Divisional application(s)EP22214115.2  / EP4215191
Fees paidRenewal fee
11.09.2020Renewal fee patent year 03
11.09.2020Renewal fee patent year 04
11.09.2020Renewal fee patent year 05
13.11.2020Renewal fee patent year 06
19.10.2021Renewal fee patent year 07
22.11.2022Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A] US2007207141  (LIEBERBURG IVAN et al.)
 [Y]   "DIMETHYL FUMARATE (TECFIDERA) AND PML RESULTING IN DEATH", 7 November 2014 (2014-11-07), pages 1 - 1, XP055247812, Retrieved from the Internet [retrieved on 20160205]
 [A]   "SUMMARY OF PRODUCT CHARACTERISTICS TECFIDERA", 11 October 2014 (2014-10-11), pages 1 - 49, XP055247806, Retrieved from the Internet [retrieved on 20160205]
 [Y]   DANIEL ONTANEDA ET AL: "Risk stratification and mitigation in multiple sclerosis", MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol. 3, no. 5, 1 September 2014 (2014-09-01), NL, pages 639 - 649, XP055596046, ISSN: 2211-0348, DOI: 10.1016/j.msard.2014.05.003

DOI:   http://dx.doi.org/10.1016/j.msard.2014.05.003
by applicantUS6436992
 WO2011085369
 WO2007100770
 WO2012166971
 US4959389
 WO2013119677
 US2014179778
 US8148414
 US2014057918
 US8669281
 WO2014096425
 US2014179779
   SCHIMRIGK ET AL., EUR. J. NEUROL., vol. 13, no. 6, 2006, pages 604 - 610
   DRUGS R&D, vol. 6, no. 4, 2005, pages 229 - 30
   GOLD ET AL., N. ENGL. J. MED., vol. 367, no. 12, 2012, pages 1087 - 1097
   VAN OOSTEN ET AL., N. ENGL. J. MED., vol. 368, no. 17, 2013, pages 1659 - 1658
   EMRICH, LISA, TECFIDERA AND PML - WHAT'S THE STORY, 25 April 2013 (2013-04-25)
   SPONZILLI ET AL., NEUROLOGY, vol. 25, no. 7, 1975, pages 664 - 668
   RANKIN ET AL., J. RHEUMATOL., vol. 22, no. 4, 1995, pages 777 - 779
   DUREZ ET AL., ARTHRITIS RHEUM., vol. 46, no. 98, 2002, pages 536
   GARRELS ET AL., AM. J. NEURORADIOL., vol. 17, no. 3, 1996, pages 597 - 600
   MAJOR ET AL., ANNU. REV. MED., vol. 61, 2010, pages 35 - 47
   "Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING
   "Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING
   JACQUES, J. ET AL.: "Enantiomers, Racemates and Resolutions", 1981, WILEY INTERSCIENCE
   WILEN, S. H. ET AL., TETRAHEDRON, vol. 33, 1977, pages 2725
   ELIEL, E. L.: "Stereochemistry of Carbon Compounds", 1962, MCGRAW HILL
   WILEN, S. H.: "Tables of Resolving Agents and Optical Resolutions", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268
   NEWTON, J. M., JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 26, 1974, pages 215 - 216
   PANDEYAPURI, KONA POWDER AND PARTICLE JOURNAL, vol. 30, 2013, pages 211 - 220
   JAROSZPARROTT, J. PHARM. SCI., vol. 72, no. 5, 1983, pages 530 - 535
   PODCZECK, INTL. J. PHARM., vol. 436, 2012, pages 214 - 232
   LACHMAN, L. ET AL.: "The Theory & Practice of Indus tira l Pharmacology", 1986, pages: 298
   DWORKIN ET AL., CURR. CLIN. TOP. INFECT. DIS., vol. 22, 2002, pages 181 - 195
   POST ET AL., AM. J. NEURORADIOL., vol. 20, no. 10, 1999, pages 1896 - 1906
   YOUSRY ET AL., N. ENGL. J. MED., vol. 354, no. 9, 2006, pages 924 - 933
   BERGER ET AL., ANN. NEURAL., vol. 44, no. 3, 1998, pages 341 - 349
   HOFFMANN ET AL., J. NEURAL. NEUROSURG. PSYCHIATRY, vol. 74, no. 8, 2003, pages 1142 - 1144
   LANGER-GOULD ET AL., N ENGL. J. MED., vol. 353, no. 4, 2005, pages 375 - 381
   HENSON ET AL., NEUROLOGY, vol. 41, no. 12, 1991, pages 1967 - 1971
   GIBSON ET AL., J. MED. VIROL., vol. 39, no. 4, 1993, pages 278 - 281
   WEBER ET AL., AIDS, vol. 8, no. 1, 1994, pages 49 - 57
   WEBER ET AL., J. INFECT. DIS., vol. 169, no. 5, 1994, pages 1138 - 1141
   VAGO ET AL., J. ACQUIR. IMM. DEFIC. SYNDR. HUM. RETROVIROL., vol. 12, no. 2, 1996, pages 139 - 146
   ELPHICK ET AL., SCIENCE, vol. 306, no. 5700, 2004, pages 1380 - 1383
   VERMA ET AL., J INFECT DIS., vol. 196, no. 5, 2007, pages 709 - 711
   GOSERT ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 55, no. 5, 2011, pages 2129 - 2136
   YOUNG ET AL., ANN. ACAD. MED. SINGAP., vol. 41, no. 12, 2012, pages 620 - 624
   CLIFFORD ET AL., J. NEUROVIROL., vol. 19, no. 4, 2013, pages 311 - 313
   KORALNIK, CURR. OPT. NEUROL., vol. 17, no. 3, 2004, pages 365 - 370
   SETH ET AL., J. NEUROVIROL., vol. 9, no. 2, 2003, pages 236 - 246
   COLLAZOS, CNS DRUGS, vol. 17, no. 12, 2003, pages 869 - 887
   MAMIDI ET AL., J. NEUROVIROL., vol. 8, no. 3, 2002, pages 158 - 167
   PRZEPIORKA ET AL., BONE MARROW TRANSPLANT, vol. 20, no. 11, 1997, pages 983 - 987
   REDINGTON ET AL., ARCH. NEURAL., vol. 59, no. 5, 2002, pages 712 - 718
   PADGETT ET AL., PROG. CLIN. BIOL. RES., vol. 105, 1983, pages 107 - 117
   BUTTARELLOPLEBANI, AM. J. CLIN. PATHOL., vol. 130, no. 1, 2008, pages 104 - 116
   KAPPOS LGOLD RMILLER DH ET AL., LANCET, vol. 372, 2008, pages 1463 - 1472
   GOLD RKAPPOS LARNOLD DL ET AL., NENGL J MED, vol. 367, 2012, pages 1098 - 1107
   FOX RJMILLER DHPHILLIPS JT ET AL., N ENGL J MED, vol. 367, 2012, pages 1087 - 1097
   GOLD RPHILLIPS JTBAR-OR A ET AL.: "Five-year follow-up of delayed-release dimethyl fumarate in RRMS: integrated clinical efficacy data from the DEFINE, CONFIRM, and ENDORSE studies", JOINT ECTRIMS-ACTRIMS MEETING, 10 September 2014 (2014-09-10), pages 110
   ARNOLD DLFOX RJHAVRDOVA E ET AL.: "Five-year follow-up of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: MRI outcomes from DEFINE, CONFIRM, and ENDORSE", JOINT ECTRIMS-ACTRIMS MEETING, 10 September 2014 (2014-09-10), pages 059
   POZZILLI CPHILLIPS JTFOX RJ ET AL.: "Long-term follow-up of the safety of delayed-release dimethyl fumarate in RRMS: interim results from the ENDORSE extension study", JOINT ECTRIMS-ACTRIMS MEETING, 10 September 2014 (2014-09-10), pages 066
   "TECFIDERATM (dimethyl fumarate) [prescribing information", December 2014, BIOGEN IDEC.
   POLMAN CHREINGOLD SCEDAN G ET AL., ANN NEUROL, vol. 58, 2005, pages 840 - 846
   "Common Terminology Criteria for Adverse Events", 29 May 2009, NATIONAL CANCER INSTITUTE
other  ANONYMOUS: "HIGHLIGHTS OF PRESCRIBING INFORMATION TECFIDERA (dimethyl fumarate) delayed-release capsules, for oral use", 3 December 2014 (2014-12-03), pages 1 - 17, XP055915602
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.